Literature DB >> 12826934

The insulin resistance syndrome and coronary artery disease.

David M Kendall1, Burton E Sobel, Ann M Coulston, Anne L Peters Harmel, Barry K McLean, Virginia Peragallo-Dittko, John B Buse, Vivian A Fonseca, James O Hill, Richard W Nesto, F Xavier Pi Sunyer.   

Abstract

Insulin resistance is an increasingly common metabolic abnormality characterized by an impaired physiological response to insulin. The constellation of insulin resistance and several other metabolic and vascular disorders is known as the insulin resistance syndrome. The characteristic features of the insulin resistance syndrome include central obesity, hypertension, dyslipidemia, glucose intolerance and specific abnormalities of both endothelial cell and vascular function. Although insulin resistance can arise in response to aging, obesity and inactivity, there is a clear genetic component. Insulin resistance is not generally attributable to a single genetic defect. Indeed, it is very likely to be a polygenic disorder in most individuals. A genetic predisposition is suggested to be the demonstration of increased insulin resistance in first-degree relatives of patients with diabetes and by a high incidence of insulin resistance in specific populations. Epidemiological data have demonstrated a strong association between a clustering of specific factors and the risk of cardiovascular disease. The diagnosis of the insulin resistance syndrome remains a significant clinical challenge. At present, clinicians are faced with establishing a clinical diagnosis despite varying definitions of the disorder and controversy regarding how many components presage clinical events. A proposed approach to the management of patients with the insulin resistance syndrome is discussed.

Entities:  

Mesh:

Year:  2003        PMID: 12826934     DOI: 10.1097/01.mca.0000076512.29238.2a

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  8 in total

1.  Second-hand Smoking and CV Risk.

Authors:  Ioana Munteanu; Florin Dumitru Mihălţan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-12

2.  Nutritional strategy to prevent fatty liver and insulin resistance independent of obesity by reducing glucose-dependent insulinotropic polypeptide responses in mice.

Authors:  Farnaz Keyhani-Nejad; Martin Irmler; Frank Isken; Eva K Wirth; Johannes Beckers; Andreas L Birkenfeld; Andreas F H Pfeiffer
Journal:  Diabetologia       Date:  2014-10-28       Impact factor: 10.122

3.  Increased prevalence of cardiovascular risk factors in newly diagnosed type 2 diabetes patients - a retrospective study.

Authors:  G Roman; G Teodorescu
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

4.  Association of Myopia With Risk of Incident Metabolic Syndrome: Findings From the UK Biobank Study Cohort of 91,591 Participants.

Authors:  Yanxian Chen; Zhuoting Zhu; Wei Wang; Xianwen Shang; Mingguang He; Jinying Li
Journal:  Front Med (Lausanne)       Date:  2022-05-16

Review 5.  Molecular studies on coronary artery disease-a review.

Authors:  A Supriya Simon; T Vijayakumar
Journal:  Indian J Clin Biochem       Date:  2013-02-12

6.  Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches.

Authors:  Christos Kalofoutis; Christina Piperi; Anastasios Kalofoutis; Fred Harris; David Phoenix; Jaipaul Singh
Journal:  Exp Clin Cardiol       Date:  2007

7.  The association of obesity with insulin resistance in male patients with obstructive sleep apnea syndrome in Korea.

Authors:  Seockhoon Chung; In-Young Yoon; Gawon Ju
Journal:  Psychiatry Investig       Date:  2011-05-26       Impact factor: 2.505

8.  Associations of Triglycerides/High-Density Lipoprotein Cholesterol Ratio With Insulin Resistance, Impaired Glucose Tolerance, and Diabetes in American Adults at Different Vitamin D3 Levels.

Authors:  Yuanyuan Liu; Rongpeng Gong; Gang Luo; Jinxia Li; Qidan Li; Lixin Yang; Xiaoxing Wei
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-04       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.